Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Retained Earnings
Cumulative profits kept in the business rather than paid out as dividends.
Sionna Therapeutics, Inc.NASDAQ: SION
Retained Earnings · Q1 FY2026 · quarter ended Mar 2026
Retained earnings remains negative
Q1 FY2026 retained earnings was -$283.13M, compared with -$197.57M a year earlier.
Context
- Retained earnings amounted to 92.8% of total assets at the end of Q1 FY2026, up 39.4 pp from a year earlier.
- Retained earnings grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether retained earnings keeps falling in the next quarterly balance sheet after a -43.3% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Retained Earnings history
USD · from the balance sheet
- Latest · FY2025
- (256.35M) USD
- Year-over-year change
- -41.6%
| Period | Period end | Retained Earnings | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (256.35M) | -41.6% |
| FY2024 | 2024-12-31 | (181.09M) | -51.7% |
| FY2023 | 2023-12-31 | (119.4M) | -65.5% |
| FY2022 | 2022-12-31 | (72.14M) | — |
Retained Earnings vs competitors
How SION compares with its peers on the latest reported figures
- SION's Mar 2026 retained earnings of -$283.13M is the 2nd highest of the 11 companies compared; the peer median is -$962.73M.
- Its year-over-year change of -43.3% is the 8th highest of 11, against a peer median of -32.3%.
- Retained earnings amounts to 92.8% of total assets for SION, versus a peer median of 178.3%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | -$168.83M | -722.1% | — | 11.3% | |
| Mar 2026 | -$283.13M | -43.3% | — | 92.8% | |
| Mar 2026 | -$375.74M | -43.8% | — | 36.5% | |
| Mar 2026 | -$513.76M | -31.3% | — | 122.4% | |
| Mar 2026 | -$669.07M | +1.8% | — | 170.7% | |
| Sep 2026 | -$940.91M | -42.9% | — | 186.1% | |
| Mar 2026 | -$984.54M | -6.3% | — | 195.1% | |
| Jun 2026 | -$991.37M | -68.2% | — | 186.0% | |
| Sep 2026 | -$1.01B | -13.9% | — | 85.8% | |
| Sep 2026 | -$2.04B | -17.8% | — | 283.0% | |
| Jun 2026 | -$2.35B | -33.2% | — | 634.5% | |
| Peer median (excluding SION) | -$962.73M | -32.3% | — | 178.3% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.